Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction

Biomaterials

Volumn 32, Issue 6, 2011, Pages 1724-1730

  Suzuki Kouyama, Emi ^a   Katayama, Kazufumi ^a,b   Sakurai, Fuminori ^a,b   Yamaguchi, Tomoko ^a,b   Kurachi, Shinnosuke ^a,b   Kawabata, Kenji ^a,b   Nakagawa, Shinsaku ^b   Mizuguchi, Hiroyuki ^a,b  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Drug delivery; Gene expression; Gene therapy; Polyethylene; Surface modification

Indexed keywords

ADENOVIRUS VECTOR; AVIDIN-BIOTIN; BACKGROUND LEVEL; BINDING PEPTIDE; CAPSID PROTEINS; IN-VITRO; INTRAVENOUS ADMINISTRATION; PEGYLATION; PHAGOCYTIC CELLS; RECOMBINANT ADENOVIRUS; RETENTION TIME; SURFACE MODIFICATION; SYSTEMIC ADMINISTRATION; TRANSDUCTION EFFICIENCY;

BACTERIOPHAGES; BLOOD; COENZYMES; DRUG DELIVERY; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; POLYETHYLENES; THERMOPLASTICS; TUMORS;

VECTORS;

ADENOVIRUS BIOTIN BINDING PEPTIDE BIOTIN AVIDIN BIOTIN POLYETHYLENE GLYCOL L2 CONJUGATE; ADENOVIRUS VECTOR; AVIDIN; BIOTIN; CAPSID PROTEIN; MACROGOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; CONJUGATION; CONTROLLED STUDY; COXSACKIE VIRUS; DRUG DELIVERY SYSTEM; DRUG TUMOR LEVEL; FEMALE; GENE EXPRESSION; GENE INSERTION; GENE THERAPY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SURFACE PROPERTY; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; AVIDIN; BIOTIN; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; POLYETHYLENE; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; COXSACKIEVIRUS; MIRIDAE;

EID: 78650262140     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.10.060     Document Type: Article

References (36)

1. Sangro B, Mazzolini G, Ruiz M, Ruiz J, Quiroga J, Herrero I, et al. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther in press.
2. Patel P., Young J.G., Mautner V., Ashdown D., Bonney S., Pineda R.G., et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol Ther 2009, 17:1292-1299.
3. Sakurai F., Mizuguchi H., Yamaguchi T., Hayakawa T. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 2003, 8:813-821.
4. Seshidhar Reddy P., Ganesh S., Limbach M.P., Brann T., Pinkstaff A., Kaloss M., et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003, 311:384-393.
5. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003, 77:8263-8271.
6. Chen P., Kovesdi I., Bruder J.T. Effective repeat administration with adenovirus vectors to the muscle. Gene Ther 2000, 7:587-595.
7. Eto Y., Gao J.Q., Sekiguchi F., Kurachi S., Katayama K., Maeda M., et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 2005, 7:604-612.
8. Gao J.Q., Eto Y., Yoshioka Y., Sekiguchi F., Kurachi S., Morishige T., et al. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Control Release 2007, 122:102-110.
9. Yao X., Yoshioka Y., Morishige T., Eto Y., Watanabe H., Okada Y., et al. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther 2009, 16:1395-1404.
10. Ogawara K., Rots M.G., Kok R.J., Moorlag H.E., Van Loenen A.M., Meijer D.K., et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 2004, 15:433-443.
11. Wortmann A., Vohringer S., Engler T., Corjon S., Schirmbeck R., Reimann J., et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther 2008, 16:154-162.
12. Hofherr S.E., Shashkova E.V., Weaver E.A., Khare R., Barry M.A. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther 2008, 16:1276-1282.
13. Yamamoto Y., Tsutsumi Y., Yoshioka Y., Nishibata T., Kobayashi K., Okamoto T., et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 2003, 21:546-552.
14. Maruyama K., Yuda T., Okamoto A., Kojima S., Suginaka A., Iwatsuru M. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochim Biophys Acta 1992, 1128:44-49.
15. Maeda H, Matsumura Y. EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv Drug Deliv Rev in press.
16. Mizuguchi H., Kay M.A. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 1998, 9:2577-2583.
17. Mizuguchi H., Kay M.A. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999, 10:2013-2017.
18. Sakurai F., Kawabata K., Yamaguchi T., Hayakawa T., Mizuguchi H. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities. Gene Ther 2005, 12:1424-1433.
19. Kurachi S., Koizumi N., Sakurai F., Kawabata K., Sakurai H., Nakagawa S., et al. Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon. Gene Ther 2007, 14:266-274.
20. Howarth M., Takao K., Hayashi Y., Ting A.Y. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc Natl Acad Sci USA 2005, 102:7583-7588.
21. Mizuguchi H., Koizumi N., Hosono T., Utoguchi N., Watanabe Y., Kay M.A., et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001, 8:730-735.
22. Maizel J.V., White D.O., Scharff M.D. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968, 36:115-125.
23. Li S., Huang L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther 1997, 4:891-900.
24. Suzuki T., Sakurai F., Nakamura S., Kouyama E., Kawabata K., Kondoh M., et al. miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol Ther 2008, 16:1719-1726.
25. Vigne E., Mahfouz I., Dedieu J.F., Brie A., Perricaudet M., Yeh P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 1999, 73:5156-5161.
26. Reche P.A. Lipoylating and biotinylating enzymes contain a homologous catalytic module. Protein Sci 2000, 9:1922-1929.
27. Waddington S.N., McVey J.H., Bhella D., Parker A.L., Barker K., Atoda H., et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132:397-409.
28. Kalyuzhniy O., Di Paolo N.C., Silvestry M., Hofherr S.E., Barry M.A., Stewart P.L., et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A 2008, 105:5483-5488.
29. Koizumi N., Mizuguchi H., Sakurai F., Yamaguchi T., Watanabe Y., Hayakawa T. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J Virol 2003, 77:13062-13072.
30. Doronin K., Shashkova E.V., May S.M., Hofherr S.E., Barry M.A. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 2009, 20:975-988.
31. Shayakhmetov D.M., Lieber A. Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol 2000, 74:10274-10286.
32. van Raaij M.J., Mitraki A., Lavigne G., Cusack S. A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein. Nature 1999, 401:935-938.
33. Vigant F., Descamps D., Jullienne B., Esselin S., Connault E., Opolon P., et al. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 2008, 16:1474-1480.
34. Trotman L.C., Mosberger N., Fornerod M., Stidwill R.P., Greber U.F. Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat Cell Biol 2001, 3:1092-1100.
35. Vlachaki M.T., Hernandez-Garcia A., Ittmann M., Chhikara M., Aguilar L.K., Zhu X., et al. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther 2002, 6:342-348.
36. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005, 174:7179-7185.